Vision RT reins in £250,000 for US push:
This article was originally published in Clinica
London, UK-based 3D imaging specialist Vision RT has secured £250,000 ($504,000) in financing from new investor The Capital Fund in a bid to support its operations in the US. "We have recently appointed a director of sales, North America, who is establishing a direct sales and marketing presence for us in the US," company founder and CEO Dr Norman Smith told Clinica. The investment, which is part of a larger financing round, will also be used to further develop the company's patent-pending technology, the GateCT and GateRT 3D tracking platforms.
You may also be interested in...
The UK has approved the mRNA-based vaccine just nine days after receiving the final Phase III results from Pfizer.
As the MHRA prepares to grant approval to the Oxford/AstraZeneca vaccine, Wockhardt is set to supply 100 million doses for the UK government’s own use and its WHO commitments. The company is also in talks with global vaccine developers to manufacture their COVID-19 vaccines for emerging economies
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.